Thought Leader Interview: Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutica; Coordinator EMIF


January 27, 2016
When it comes to sharing health data, solving the technical solutions of data sharing is more straightforward than structuring workable collaboration models that satisfy both data owners and researchers alike, says Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutica; Coordinator EMIF.

Thought Leader Interview: Bart Vannieuwenhuyse, Senior Director Health Information Sciences, Janssen Pharmaceutica; Coordinator EMIF2018-03-07T07:54:52+02:00

4th EMA-EBE joint Regulatory Policy Seminar: Emerging Medicinal Products – from Laboratory to Patient use


December 14, 2015
Europe’s world-leading science base is fuelling innovation in advanced therapies, which a growing volume of clinical data indicates will address a diversity of unmet medical needs, delivering better health and generating economic benefits.



4th EMA-EBE joint Regulatory Policy Seminar: Emerging Medicinal Products – from Laboratory to Patient use2018-03-07T07:58:47+02:00

Interview with Keith Thompson, CEO of the UK Cell Therapy Catapult: Advanced therapies stand poised to change the drug discovery and development paradigm


November 25, 2015
After years of painstaking research, cell, gene and tissue therapies are turning in unprecedented evidence of efficacy in phase I/II. Unlike the old model, where the sole focus would now be on phase III, companies need to work simultaneously on manufacturing, logistics, pricing and getting the product to the patient, says Keith Thompson.

Interview with Keith Thompson, CEO of the UK Cell Therapy Catapult: Advanced therapies stand poised to change the drug discovery and development paradigm2018-03-06T15:04:57+02:00

Views from Eduardo Bravo of TiGenix: Allogeneic stem cell therapy makes a breakthrough in the clinic and is poised to address unmet medical need


November 25, 2015
Positive data in the phase III trial of TiGenix’s Cx601 allogeneic cell therapy indicates it could provide a one-off treatment for complex perianal fistulas, a complication of Crohn’s disease. The results open up a completely new avenue for treatment of patients who do not respond to existing therapies, says Eduardo Bravo, CEO of Tigenix.

Views from Eduardo Bravo of TiGenix: Allogeneic stem cell therapy makes a breakthrough in the clinic and is poised to address unmet medical need2018-03-06T15:05:52+02:00

Interview with Emil Pot, co-founder of ActoGeniX: Europe needs larger investment funds to create a funding escalator from phase II to phase III


November 19, 2015
With more companies advancing innovative therapies to the end of phase II, the funding requirements of European biotech are spiralling. A new initiative is required to create large and liquid funds to support the next stage of growth and ensure Europe reaps the benefits – both medical and commercial – of its excellent research, says Emil Pot.

Interview with Emil Pot, co-founder of ActoGeniX: Europe needs larger investment funds to create a funding escalator from phase II to phase III2018-03-06T15:07:27+02:00

Report from the Alliance for Regenerative Medicine (ARM) Investor Day in London: As cell and gene therapies turn in positive clinical data, attention turns to delivery to patients


November 12, 2015 - London
After huge investment in the basic science and translation to the clinic, Europe’s advanced therapies companies are accumulating data, which indicate these products have an unprecedented effect. Now effort is needed to develop manufacturing, organise logistics, agree reimbursement and ensure patients get the benefits. Vital Transformation reports for EBE from the ARM Conference.

Report from the Alliance for Regenerative Medicine (ARM) Investor Day in London: As cell and gene therapies turn in positive clinical data, attention turns to delivery to patients2018-03-06T15:08:16+02:00

Press Release: Better Science, Better Health Conference to Promote International Collaboration to Accelerate New Models in Healthcare


October 22, 2015 – Washington D.C.
Vital Transformation is pleased to announce the Better Science, Better Health: New Healthcare Models Conference, which aims to promote international collaboration to accelerate new models in healthcare. Taking place in Washington D.C., from 27-28th October, the Conference features thought leaders who will help shape the future of healthcare in both Europe and the United States.

Press Release: Better Science, Better Health Conference to Promote International Collaboration to Accelerate New Models in Healthcare2018-03-06T15:10:58+02:00

Event Report – MAPPs: Saving Time, Saving Lives


June 17th, 2015 – by Duane Schulthess
While progress is often slow and laborious when trying to gain traction for new ideas in the ‘Brussels Bubble’, there was much to be optimistic about in the Medicine’s Adaptive Pathways to Patients (MAPPs) meeting held on Thursday June 4 in Luxembourg. Organised as part of EFPIA’s general assembly, a broad cross section of stakeholders attended the MAPPs session to hear what had been accomplished over the last twelve months and discover how the initiative is being moved forward in partnership with the second Innovative Medicines Initiative (IMI2) and the European Medicine’s Agency (EMA).

Event Report – MAPPs: Saving Time, Saving Lives2018-03-06T15:12:48+02:00

Press Release: Healthcare Consultancy Vital Transformation Expands to United States with Opening of Washington D.C. Office


May 29th, 2015 - by Vital TransformationHealthcare consultancy Vital Transformation is expanding to the United States with the addition of a new partner to head its operations in Washington D.C. Joseph P. Hammang, Ph.D., will join the Vital Transformation team, overseeing the company’s work in the U.S. and supporting its growing presence in Europe.

Press Release: Healthcare Consultancy Vital Transformation Expands to United States with Opening of Washington D.C. Office2018-03-06T15:13:40+02:00
Go to Top